Adial Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
Adial Pharmaceuticals, Inc. carries a market capitalization of 2.23M, placing it among publicly traded companies globally. Its enterprise value stands at -2.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.23M |
| Enterprise Value | -2.98M |
Share Statistics
Adial Pharmaceuticals, Inc. currently has 1.51M shares outstanding.
| Shares Outstanding | 1.51M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.02 |
| P/TBV Ratio | 0.43 |
| P/FCF Ratio | -0.25 |
| P/OCF Ratio | -0.25 |
Financial Position
Adial Pharmaceuticals, Inc. maintains a current ratio of 3.18, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.18 |
| Quick Ratio | 3.04 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -179.08 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Adial Pharmaceuticals, Inc.'s stock has declined approximately -85.93939% over the past 52 weeks. The 50-day moving average sits at 1.74, while the 200-day moving average is 5.48.
| Beta (5Y) | N/A |
| 52-Week Price Change | -85.93939% |
| 50-Day Moving Average | 1.74 |
| 200-Day Moving Average | 5.48 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -7.53M, while operating income came in at -7.53M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -7.53M |
| Pretax Income | -7.77M |
| Net Income | -7.77M |
| EBITDA | -7.53M |
| EBIT | -7.53M |
| Earnings Per Share (EPS) | -8.69 |
Balance Sheet
Total book value stands at -91.99M, with working capital of 3.29M providing operational flexibility.
| Cash & Cash Equivalents | 4.58M |
| Total Debt | N/A |
| Net Debt | -4.58M |
| Equity (Book Value) | -91.99M |
| Book Value Per Share | -102.91 |
| Working Capital | 3.29M |
Cash Flow
Adial Pharmaceuticals, Inc. produced -6.52M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.52M |
| Capital Expenditures | N/A |
| Free Cash Flow | -6.52M |
| FCF Per Share | -7.29 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -546.06 |
| FCF Yield | -407.43 |
Stock Splits
Adial Pharmaceuticals, Inc.'s most recent stock split took place on February 6, 2026 with a 25:1 split ratio.
| Last Split Date | 2/6/2026 |
| Split Ratio | 25:1 |
Scores
Adial Pharmaceuticals, Inc. posts an Altman Z-Score of -28.02, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -28.02 |